BMTHeader

{short description of image}
Issue #68 Vol.16, No. 3
October 2005
Printable Version
Download Adobe Acrobat Reader
Transplant Centers Rise to Hurricane Challenge
Study Finds Overall Health and Quality of Life Intact 10 Years after Transplant
Can You Tell Us What Pediatric Bone Marrow Transplant Families Need?
Fill Next Year with Miracles.
BMT InfoNet Teams Up with Transplant Survivor to Help Katrina Victims
New Patient Resources from the National Marrow Donor Program
Meet Garrett Carroll
Novel Treatment for GVHD
Attention Scleroderma Patients
Your Turn
Special Thanks
Newsbits
Order Form

——ADVERTISEMENT——


Novel Treatment for GVHD

Graft vs. Host Disease (GVHD) is a potentially life threatening immune condition that can affect patients who have received a bone marrow transplant.

Osiris Therapeutics, Inc. is currently enrolling patients in a Phase II clinical trial designed to test the efficacy of adult stem cells in treating GVHD. The cellular component of the drug is derived from the bone marrow of healthy adult donors. Data from previously treated GVHD patients and non-clinical evidence suggest that this novel therapy will address both the immune response of donor cells as well as tissue damage resulting from inflammation, radiation and/or chemotherapy.

For more information about the Osiris GVHD clinical trial, please visit our website at www.osiristx.com or contact us via e-mail at Prochymal@osiristx.com.


——ADVERTISEMENT——

archivetopfillnext
Attention Scleroderma Patients